Royalty Pharma (RPRX) to Announce Quarterly Earnings on Wednesday

Royalty Pharma (NASDAQ:RPRX) is expected to be releasing its Q2 2026 results before the market opens on Wednesday, August 5th. Analysts expect the company to post earnings of $1.27 per share and revenue of $758.9270 million for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The business had revenue of $630.58 million during the quarter, compared to analyst estimates of $881.69 million. On average, analysts expect Royalty Pharma to post $5 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Royalty Pharma Price Performance

NASDAQ RPRX opened at $59.97 on Wednesday. The business has a 50 day simple moving average of $55.88 and a 200 day simple moving average of $49.54. Royalty Pharma has a 52-week low of $34.08 and a 52-week high of $60.08. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. The stock has a market cap of $34.53 billion, a price-to-earnings ratio of 40.80, a PEG ratio of 10.40 and a beta of 0.43.

Royalty Pharma Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be paid a $0.235 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $0.94 dividend on an annualized basis and a yield of 1.6%. Royalty Pharma’s payout ratio is presently 63.95%.

Insider Transactions at Royalty Pharma

In other Royalty Pharma news, Director Gregory Norden sold 3,045 shares of the company’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.00, for a total transaction of $161,385.00. Following the completion of the transaction, the director owned 191,803 shares of the company’s stock, valued at $10,165,559. This represents a 1.56% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Terrance P. Coyne sold 64,399 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $53.98, for a total transaction of $3,476,258.02. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 393,009 shares of company stock worth $21,601,827. 18.84% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Compound Planning Inc. increased its stake in Royalty Pharma by 21.7% in the 4th quarter. Compound Planning Inc. now owns 10,618 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 1,896 shares during the last quarter. Corient Private Wealth LLC lifted its position in Royalty Pharma by 26.8% during the 4th quarter. Corient Private Wealth LLC now owns 154,922 shares of the biopharmaceutical company’s stock worth $5,986,000 after buying an additional 32,766 shares in the last quarter. Mercer Global Advisors Inc. ADV boosted its stake in shares of Royalty Pharma by 25.2% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 17,177 shares of the biopharmaceutical company’s stock worth $664,000 after buying an additional 3,452 shares during the last quarter. Achmea Investment Management B.V. acquired a new position in shares of Royalty Pharma during the 4th quarter worth about $1,321,000. Finally, Delta Global Management LP acquired a new position in shares of Royalty Pharma during the 4th quarter worth about $1,712,000. Institutional investors and hedge funds own 54.35% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on the stock. Morgan Stanley upped their price target on shares of Royalty Pharma from $61.00 to $63.00 and gave the company an “overweight” rating in a report on Friday, April 10th. UBS Group boosted their price objective on shares of Royalty Pharma from $51.00 to $57.00 and gave the company a “buy” rating in a research report on Tuesday, April 21st. Weiss Ratings lowered shares of Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, May 15th. Citigroup upped their target price on shares of Royalty Pharma from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Seven equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus target price of $56.57.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.